Gene · 140
Papers1,628
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 1,628
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrative genomic analysis facilitates precision strategies for glioblastoma treatment. | iScience | 2022 | 36300002 | PubTator, text mining | PubMed |
| Knowing the Enemy Is Halfway towards Victory: A Scoping Review on Opioid-Induced Hyperalgesia. | J Clin Med | 2022 | 36294488 | PubTator, text mining | PubMed |
| Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma. | Cancers (Basel) | 2022 | 36291758 | PubTator, text mining | PubMed |
| Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applications. | Front Pharmacol | 2022 | 36278183 | PubTator, text mining | PubMed |
| Identification of a six-gene prognostic signature for bladder cancer associated macrophage. | Front Immunol | 2022 | 36275756 | PubTator, text mining | PubMed |
| Discovery and Structure-Activity Relationship Studies of Novel Adenosine A1 Receptor-Selective Agonists. | J Med Chem | 2022 | 36270633 | PubTator, text mining | PubMed |
| Effects of Purinergic Receptor Deletion or Pharmacologic Modulation on Pulmonary Inflammation in Mice. | ACS Pharmacol Transl Sci | 2022 | 36268115 | PubTator, text mining | PubMed |
| Identification pyroptosis-related gene signature to predict prognosis and associated regulation axis in colon cancer. | Front Pharmacol | 2022 | 36249755 | PubTator, text mining | PubMed |
| Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients. | Front Immunol | 2022 | 36248842 | PubTator, text mining | PubMed |
| Adenosine receptors as emerging therapeutic targets for diabetic kidney disease. | Kidney Res Clin Pract | 2022 | 36239063 | PubTator, text mining | PubMed |
| Chinese Cordyceps: Bioactive Components, Antitumor Effects and Underlying Mechanism-A Review. | Molecules | 2022 | 36235111 | PubTator, text mining | PubMed |
| Platelets and the Cybernetic Regulation of Ischemic Inflammatory Responses through PNC Formation Regulated by Extracellular Nucleotide Metabolism and Signaling. | Cells | 2022 | 36230973 | PubTator, text mining | PubMed |
| A2A adenosine receptor agonist reduced MMP8 expression in healthy M2-like macrophages but not in macrophages from ankylosing spondylitis patients. | BMC Musculoskelet Disord | 2022 | 36221125 | PubTator, text mining | PubMed |
| Transcription profiling of feline mammary carcinomas and derived cell lines reveals biomarkers and drug targets associated with metabolic and cell cycle pathways. | Sci Rep | 2022 | 36220861 | PubTator, text mining | PubMed |
| Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y12 Receptor Antagonists. | Korean Circ J | 2022 | 36217596 | PubTator, text mining | PubMed |
| Emerging roles of purinergic signaling in anti-cancer therapy resistance. | Front Cell Dev Biol | 2022 | 36200041 | PubTator, text mining | PubMed |
| Network Pharmacology and Molecular Docking to Explore the Mechanism of Kangxian Decoction for Epilepsy. | Evid Based Complement Alternat Med | 2022 | 36193133 | PubTator, text mining | PubMed |
| Adenosine signaling: Optimal target for gastric cancer immunotherapy. | Front Immunol | 2022 | 36189223 | PubTator, text mining | PubMed |
| Association of adenosine signaling gene signature with estrogen receptor-positive breast and prostate cancer bone metastasis. | Front Med (Lausanne) | 2022 | 36186774 | PubTator, text mining | PubMed |
| Anti-obesity effects of the dual-active adenosine A2A/A3 receptor-ligand LJ-4378. | Int J Obes (Lond) | 2022 | 36167764 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/140/papers?page=13